Trial · NCT06092333
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
NCT06092333, Phase 2, Active not recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B. Trials, record NCT06092333. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06092333
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
- NCT number
- NCT06092333
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Conditions
- Chronic Hepatitis B
- Interventions
- VIR-2218 and peginterferon alfa-2a
- First posted
- 2023-10-23
- Last updated
- 2026-10-05
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Decline in log quantitative HBsAg level | 6 months after discontinuation of all treatment | To evaluate the effect of administration of VIR-2218 in combination with peginterferon alfa-2a on qHBsAg levels |
| Secondary | Changes in innate and adaptive host immune responses to HBV during and after treatment. | Within the first 6 hours after peginterferon injection; Baseline to week 12, from Baseline to week 36 and from Baseline to week 84 | To evaluate the effects of VIR-2218 in combination with peginterferon alfa-2a on peripheral and intrahepatic immune responses in non-cirrhotic adults with chronic HBV infection |
| Secondary | HBV DNA <10 IU/ml at end of treatment and 6 months off treatment. The response will be reported as HBV DNA <LLOQ target detected (TD) or target not detected (TND) | 6 months off-treatment | Partial cure. An alternative goal of treatment of chronic hepatitis B |
| Secondary | Functional cure which is defined as undetectable HBsAg (<0.085 IU/ml) AND sustained suppression of HBV DNA [< LLOQ], <10 IU/ml)] for more than 6 months after discontinuation of all treatment | > 6 months after discontinuation of all treatment | The goal of treatment of chronic hepatitis B |
| Secondary | Safety | End of treatment 6 months off-treatment | To evaluate the safety and tolerability of VIR-2218 in combination with peginterferon alfa-2a in non-cirrhotic adults with chronic HBV infection |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06092333
GET https://conductscience.org/api/trials/v1/NCT06092333/registered